Nektar Therapeutics (0UNL.L)
USD 0.84
(0.63%)
USD 0.84
(0.63%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 267.04 Million USD | -22.36% |
| 2022 | 343.96 Million USD | -21.41% |
| 2021 | 437.68 Million USD | -5.16% |
| 2020 | 461.47 Million USD | -19.32% |
| 2019 | 571.96 Million USD | 32.22% |
| 2018 | 432.59 Million USD | 2.75% |
| 2017 | 421.03 Million USD | -12.42% |
| 2016 | 480.74 Million USD | -3.0% |
| 2015 | 495.63 Million USD | 22.29% |
| 2014 | 405.28 Million USD | -22.72% |
| 2013 | 524.43 Million USD | 16.34% |
| 2012 | 450.77 Million USD | 10.28% |
| 2011 | 408.73 Million USD | -5.07% |
| 2010 | 430.56 Million USD | -9.0% |
| 2009 | 473.15 Million USD | 27.75% |
| 2008 | 370.38 Million USD | -27.47% |
| 2007 | 510.66 Million USD | -5.63% |
| 2006 | 541.11 Million USD | 1.76% |
| 2005 | 531.74 Million USD | 91.56% |
| 2004 | 277.57 Million USD | -38.67% |
| 2003 | 452.59 Million USD | 13.19% |
| 2002 | 399.86 Million USD | 0.74% |
| 2001 | 396.92 Million USD | 12.87% |
| 2000 | 351.65 Million USD | 150.87% |
| 1999 | 140.17 Million USD | 653.03% |
| 1998 | 18.61 Million USD | -17.88% |
| 1997 | 22.66 Million USD | 254.2% |
| 1996 | 6.4 Million USD | 113.33% |
| 1995 | 3 Million USD | 66.67% |
| 1994 | 1.8 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 263.64 Million USD | -2.1% |
| 2024 Q1 | 269.3 Million USD | 0.85% |
| 2023 Q2 | 297.32 Million USD | -7.34% |
| 2023 Q3 | 282.87 Million USD | -4.86% |
| 2023 Q4 | 267.04 Million USD | -5.6% |
| 2023 Q1 | 320.87 Million USD | -6.71% |
| 2023 FY | 267.04 Million USD | -22.36% |
| 2022 Q4 | 343.96 Million USD | -6.73% |
| 2022 Q1 | 416.22 Million USD | -4.9% |
| 2022 FY | 343.96 Million USD | -21.41% |
| 2022 Q3 | 368.78 Million USD | -8.55% |
| 2022 Q2 | 403.25 Million USD | -3.12% |
| 2021 Q4 | 437.68 Million USD | -7.99% |
| 2021 FY | 437.68 Million USD | -5.16% |
| 2021 Q1 | 462.05 Million USD | 0.13% |
| 2021 Q2 | 466.37 Million USD | 0.94% |
| 2021 Q3 | 475.7 Million USD | 2.0% |
| 2020 Q4 | 461.47 Million USD | 36.66% |
| 2020 Q2 | 338.63 Million USD | -42.75% |
| 2020 Q3 | 337.68 Million USD | -0.28% |
| 2020 Q1 | 591.5 Million USD | 3.42% |
| 2020 FY | 461.47 Million USD | -19.32% |
| 2019 Q4 | 571.96 Million USD | -4.61% |
| 2019 FY | 571.96 Million USD | 32.22% |
| 2019 Q1 | 532.97 Million USD | 23.2% |
| 2019 Q2 | 542.49 Million USD | 1.79% |
| 2019 Q3 | 599.58 Million USD | 10.52% |
| 2018 Q4 | 432.59 Million USD | -5.75% |
| 2018 Q1 | 438.5 Million USD | 4.15% |
| 2018 Q3 | 458.97 Million USD | 1.39% |
| 2018 FY | 432.59 Million USD | 2.75% |
| 2018 Q2 | 452.67 Million USD | 3.23% |
| 2017 Q1 | 483.73 Million USD | 0.62% |
| 2017 FY | 421.03 Million USD | -12.42% |
| 2017 Q4 | 421.03 Million USD | -15.44% |
| 2017 Q3 | 497.89 Million USD | 5.38% |
| 2017 Q2 | 472.47 Million USD | -2.33% |
| 2016 Q3 | 492.94 Million USD | -1.87% |
| 2016 FY | 480.74 Million USD | -3.0% |
| 2016 Q2 | 502.35 Million USD | 2.07% |
| 2016 Q1 | 492.15 Million USD | -0.7% |
| 2016 Q4 | 480.74 Million USD | -2.48% |
| 2015 FY | 495.63 Million USD | 22.29% |
| 2015 Q1 | 421.9 Million USD | 4.1% |
| 2015 Q2 | 421.56 Million USD | -0.08% |
| 2015 Q3 | 410.19 Million USD | -2.7% |
| 2015 Q4 | 495.63 Million USD | 20.83% |
| 2014 Q3 | 429.68 Million USD | -16.32% |
| 2014 Q2 | 513.49 Million USD | 3.36% |
| 2014 Q1 | 496.82 Million USD | -5.26% |
| 2014 Q4 | 405.28 Million USD | -5.68% |
| 2014 FY | 405.28 Million USD | -22.72% |
| 2013 Q3 | 433.28 Million USD | -4.43% |
| 2013 Q1 | 450.52 Million USD | -0.06% |
| 2013 Q4 | 524.43 Million USD | 21.04% |
| 2013 FY | 524.43 Million USD | 16.34% |
| 2013 Q2 | 453.35 Million USD | 0.63% |
| 2012 Q1 | 532.3 Million USD | 30.23% |
| 2012 FY | 450.77 Million USD | 10.28% |
| 2012 Q4 | 450.77 Million USD | 1.04% |
| 2012 Q3 | 446.12 Million USD | -16.79% |
| 2012 Q2 | 536.15 Million USD | 0.72% |
| 2011 Q1 | 423.24 Million USD | -1.7% |
| 2011 FY | 408.73 Million USD | -5.07% |
| 2011 Q4 | 408.73 Million USD | -2.05% |
| 2011 Q3 | 417.29 Million USD | -0.54% |
| 2011 Q2 | 419.57 Million USD | -0.87% |
| 2010 Q1 | 443.75 Million USD | -6.21% |
| 2010 FY | 430.56 Million USD | -9.0% |
| 2010 Q3 | 395.52 Million USD | -6.07% |
| 2010 Q2 | 421.1 Million USD | -5.1% |
| 2010 Q4 | 430.56 Million USD | 8.86% |
| 2009 Q4 | 473.15 Million USD | 36.53% |
| 2009 Q2 | 342.4 Million USD | -1.23% |
| 2009 FY | 473.15 Million USD | 27.75% |
| 2009 Q1 | 346.66 Million USD | -6.4% |
| 2009 Q3 | 346.55 Million USD | 1.21% |
| 2008 Q1 | 468.07 Million USD | -8.34% |
| 2008 FY | 370.38 Million USD | -27.47% |
| 2008 Q2 | 465.79 Million USD | -0.49% |
| 2008 Q3 | 459.72 Million USD | -1.3% |
| 2008 Q4 | 370.38 Million USD | -19.43% |
| 2007 Q4 | 510.66 Million USD | -10.0% |
| 2007 FY | 510.66 Million USD | -5.63% |
| 2007 Q1 | 503.11 Million USD | -7.02% |
| 2007 Q2 | 514.78 Million USD | 2.32% |
| 2007 Q3 | 567.38 Million USD | 10.22% |
| 2006 FY | 541.11 Million USD | 1.76% |
| 2006 Q1 | 534.73 Million USD | 0.56% |
| 2006 Q4 | 541.11 Million USD | 0.52% |
| 2006 Q3 | 538.33 Million USD | -4.19% |
| 2006 Q2 | 561.88 Million USD | 5.08% |
| 2005 Q4 | 531.74 Million USD | 3.69% |
| 2005 Q1 | 270.18 Million USD | -2.66% |
| 2005 FY | 531.74 Million USD | 91.56% |
| 2005 Q2 | 272.73 Million USD | 0.94% |
| 2005 Q3 | 512.8 Million USD | 88.03% |
| 2004 Q2 | 263.55 Million USD | -4.58% |
| 2004 FY | 277.57 Million USD | -38.67% |
| 2004 Q4 | 277.57 Million USD | 6.37% |
| 2004 Q3 | 260.96 Million USD | -0.98% |
| 2004 Q1 | 276.19 Million USD | -38.98% |
| 2003 Q4 | 452.59 Million USD | -4.58% |
| 2003 Q3 | 474.33 Million USD | 3.15% |
| 2003 Q2 | 459.82 Million USD | 22.1% |
| 2003 Q1 | 376.6 Million USD | -5.82% |
| 2003 FY | 452.59 Million USD | 13.19% |
| 2002 Q4 | 399.86 Million USD | 2.56% |
| 2002 Q2 | 394.83 Million USD | -0.43% |
| 2002 Q1 | 396.53 Million USD | -0.1% |
| 2002 Q3 | 389.88 Million USD | -1.25% |
| 2002 FY | 399.86 Million USD | 0.74% |
| 2001 Q3 | 383.1 Million USD | -2.73% |
| 2001 Q4 | 396.92 Million USD | 3.61% |
| 2001 FY | 396.92 Million USD | 12.87% |
| 2001 Q1 | 366.61 Million USD | 4.25% |
| 2001 Q2 | 393.86 Million USD | 7.43% |
| 2000 Q2 | 275.06 Million USD | -1.2% |
| 2000 Q4 | 351.65 Million USD | 32.12% |
| 2000 Q1 | 278.41 Million USD | 98.62% |
| 2000 Q3 | 266.15 Million USD | -3.24% |
| 2000 FY | 351.65 Million USD | 150.87% |
| 1999 Q2 | 21.6 Million USD | 5.03% |
| 1999 Q3 | 22.22 Million USD | 2.86% |
| 1999 Q4 | 140.17 Million USD | 530.75% |
| 1999 FY | 140.17 Million USD | 653.03% |
| 1999 Q1 | 20.57 Million USD | 10.51% |
| 1998 Q4 | 18.61 Million USD | 15.09% |
| 1998 Q2 | 18.83 Million USD | -7.42% |
| 1998 FY | 18.61 Million USD | -17.88% |
| 1998 Q1 | 20.34 Million USD | -10.26% |
| 1998 Q3 | 16.17 Million USD | -14.12% |
| 1997 Q4 | 22.66 Million USD | 51.1% |
| 1997 Q1 | 9.39 Million USD | 46.72% |
| 1997 FY | 22.66 Million USD | 254.2% |
| 1997 Q2 | 12.78 Million USD | 36.18% |
| 1997 Q3 | 15 Million USD | 17.33% |
| 1996 Q3 | 3.5 Million USD | 6.06% |
| 1996 FY | 6.4 Million USD | 113.33% |
| 1996 Q1 | 2.9 Million USD | -3.33% |
| 1996 Q4 | 6.4 Million USD | 82.86% |
| 1996 Q2 | 3.3 Million USD | 13.79% |
| 1995 FY | 3 Million USD | 66.67% |
| 1995 Q1 | 3 Million USD | 66.67% |
| 1995 Q2 | 2.7 Million USD | -10.0% |
| 1995 Q3 | 2.6 Million USD | -3.7% |
| 1995 Q4 | 3 Million USD | 15.38% |
| 1994 FY | 1.8 Million USD | 0.0% |
| 1994 Q3 | 2.6 Million USD | 18.18% |
| 1994 Q4 | 1.8 Million USD | -30.77% |
| 1994 Q1 | 2.1 Million USD | 0.0% |
| 1994 Q2 | 2.2 Million USD | 4.76% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| uniQure N.V. | 624.01 Million USD | 57.205% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -111.775% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 56.768% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -0.873% |
| bluebird bio, Inc. | 424.62 Million USD | 37.11% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -288.38% |
| Imunon, Inc. | 8.53 Million USD | -3030.512% |
| Editas Medicine, Inc. | 150.05 Million USD | -77.964% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 98.702% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 92.382% |
| Myriad Genetics, Inc. | 312.9 Million USD | 14.655% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 73.804% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 45.217% |
| Verastem, Inc. | 71.18 Million USD | -275.144% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.612% |
| Waters Corporation | 3.47 Billion USD | 92.319% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 99.485% |
| Biogen Inc. | 12.04 Billion USD | 97.783% |
| Perrigo Company plc | 6.04 Billion USD | 95.58% |
| Dynavax Technologies Corporation | 375.02 Million USD | 28.792% |
| Illumina, Inc. | 4.36 Billion USD | 93.884% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -659.147% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -36.43% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -4.12% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -616.095% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 85.871% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -223.955% |
| Evolus, Inc. | 209.68 Million USD | -27.355% |
| Adicet Bio, Inc. | 37.12 Million USD | -619.413% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -563.864% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 96.243% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 59.587% |
| FibroGen, Inc. | 585.72 Million USD | 54.408% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 94.57% |
| OPKO Health, Inc. | 622.47 Million USD | 57.1% |
| Homology Medicines, Inc. | 118.53 Million USD | -125.293% |
| Geron Corporation | 146.12 Million USD | -82.749% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 93.407% |
| Exelixis, Inc. | 678.44 Million USD | 60.639% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -1230.507% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -2030.573% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -6.474% |
| Zoetis Inc. | 9.29 Billion USD | 97.127% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 32.778% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -443.041% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 94.814% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -451.235% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 89.742% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 88.897% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -132.594% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 83.81% |
| Blueprint Medicines Corporation | 918.64 Million USD | 70.93% |
| Insmed Incorporated | 1.66 Billion USD | 83.93% |
| TG Therapeutics, Inc. | 169.08 Million USD | -57.936% |
| Incyte Corporation | 1.59 Billion USD | 83.229% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | 77.476% |